Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103570 | 1.00 | ALDH1A1 (0.41) | ALDH1A1PREPPSEN1PSEN2APH1B | |
| SCHEMBL3103654 | 0.81 | PREP (0.43) | ALDH1A1PREPPSEN1PSEN2APH1B | |
| SCHEMBL13244922 | 0.78 | ALDH1A1 (0.44) | ALDH1A1PREP | |
| SCHEMBL7845558 | 0.78 | ALDH1A1 (0.44) | ALDH1A1PREP | |
| SCHEMBL4701620 | 0.78 | ALDH1A1 (0.44) | ALDH1A1PREP | |
| Hydrochloric Acid SCHEMBL4701828 | 0.77 | ALDH1A1 (0.43) | ALDH1A1PREP | |
| Hydrochloric Acid SCHEMBL4700390 | 0.77 | ALDH1A1 (0.43) | ALDH1A1PREP | |
| SCHEMBL13244810 | 0.75 | ALDH1A1 (0.42) | ALDH1A1PREP | |
| SCHEMBL12494674 | 0.75 | ALDH1A1 (0.51) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL12494683 | 0.75 | ALDH1A1 (0.51) | ALDH1A1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| EP-2089365-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008045668-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | ALDH1A1 530/4885PREP 35/4885PSEN1 363/4885 |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | ALDH1A1 530/4885PREP 35/4885PSEN1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.